Similar to quizartinib and gilteritinib, the combination of azacitidine with sorafenib also synergistically inhibited MOLM-13 and MV4-11 cell growth, induced apoptosis, and decreased tumor volume in xenograft mouse model of FLT3-ITD AML. This evidence concerns the gene FLT3 and neoplasm.